Use of biologics during the COVID-19 pandemic: lessons learned from psoriasis

References

• Gisondi P, Geat D, Pizzolato M, et al. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019;46:90–99.
   PubMed Web of Science ®Google Scholar
• Penso L, Dray-Spira R, Weill A, et al. Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic. Br J Dermatol. 2021;185(3):671–673.
   PubMed Web of Science ®Google Scholar
• Burlando M, Carmisciano L, Cozzani E, et al. A survey of psoriasis patients on biologics during COVID-19: a single centre experience. J Dermatolog Treat. 2022;33(1):596.
   PubMed Web of Science ®Google Scholar
• Camela E, Fabbrocini G, Cinelli E, et al. Biologic therapies, psoriasis, and COVID-19: our experience at the psoriasis unit of the university of Naples Federico II. Dermatology. 2021;237(1):13–14.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Chiricozzi A, et al. The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments. Vaccines (Basel). 2020;8(4):728.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969.
   PubMed Web of Science ®Google Scholar
• Jin Y, Lee H, Lee MP, et al. Risk of hospitalized serious infection after initiating ustekinumab or other biologics for psoriasis or psoriatic arthritis. Arthritis Care Res (Hoboken). 2021. 10.1002/acr.24630. In Print.
   PubMedGoogle Scholar
• Piaserico S, Gisondi P, Cazzaniga S, et al. Lack of evidence for an increased risk of severe COVID-19 in psoriasis patients on biologics: a cohort study from northeast Italy. Am J Clin Dermatol. 2020;21(5):749–751.
   PubMed Web of Science ®Google Scholar
• Brazzelli V, Isoletta E, Barak O, et al. Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone. Dermatol Ther. 2020;33(6):e14516.
   PubMed Web of Science ®Google Scholar
• Ahmed SMA, Volontè M, Isoletta E, et al. SARS-CoV-2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone. J Eur Acad Dermatol Venereol. 2022;36(2):e86–e88.
   PubMed Web of Science ®Google Scholar
• Gracia-Darder I, Garcías-Ladaria J, Ramos Rodríguez D, et al. Biologic therapy for psoriasis during the COVID-19 pandemic: a case series of patients treated in Hospital Universitario Son Espases. Actas Dermosifiliogr. 2022;113(1):110–112.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Chiricozzi A, et al. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021;21(2):271–277.
   PubMed Web of Science ®Google Scholar
• Damiani G, Pacifico A, Bragazzi NL, et al. Biologics increase the risk of SARS - CoV −2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Zaza G, Del Giglio M, et al. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. J Am Acad Dermatol. 2020;83(1):285–287.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Piaserico S, Naldi L, et al. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience. J Allergy Clin Immunol. 2021;147(2):558–560.e1.
   PubMed Web of Science ®Google Scholar
• Ciechanowicz P, Dopytalska K, and Mikucka-Wituszyńska A, et al. The prevalence of SARS-CoV-2 infection and the severity of the course of COVID-19 in patients with psoriasis treated with biologic therapy. J Dermatol Treat. 2022;33(3) :1581–1584.
   Web of Science ®Google Scholar
• Polat AK, Topal IO, Karadag AS, et al. The impact of COVID-19 in patients with psoriasis: a multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691.
   PubMed Web of Science ®Google Scholar
• Fougerousse AC, Perrussel M, Bécherel PA, et al. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID‐19. J Eur Acad Dermatol Venereol. 2020;34(11):e676‐e679.
   Web of Science ®Google Scholar
• Penso L, Dray-Spira R, Weill A, et al. Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France. Br J Dermatol. 2022;186(1):59–68.
   PubMed Web of Science ®Google Scholar
• MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol. 2022;4(7):e490–e506.
   PubMedGoogle Scholar
• Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60–71.
   PubMed Web of Science ®Google Scholar
• Chima M, Lebwohl M. TNF inhibitors for psoriasis. Semin Cutan Med Surg. 2018;37(3):134–142.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7(3):e012567.
   PubMed Web of Science ®Google Scholar
• Kim S, Solomon D. Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol. 2010;6(3):165–174.
   PubMed Web of Science ®Google Scholar
• Syed MN, Shah M, Shin DB, et al. Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2021;84(1):161–163.
   PubMed Web of Science ®Google Scholar
• Kridin K, Schonmann Y, Damiani G, et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Dermatol Ther. 2021;34(4):e15003.
   PubMed Web of Science ®Google Scholar
• Pahalyants V, Murphy WS, Klebanov N, et al. Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: a retrospective matched cohort study from Massachusetts. J Am Acad Dermatol. 2022;86(1):252–255.
   PubMed Web of Science ®Google Scholar
• Criado PR, Ianhez M, Silva de Castro CC, et al. COVID-19 and skin diseases: results from a survey of 843 patients with atopic dermatitis, psoriasis, vitiligo and chronic urticaria. J Eur Acad Dermatol Venereol. 2022;36(1):e1–e3.
   PubMed Web of Science ®Google Scholar
• Yousaf A, Gayam S, Feldman S, et al. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: a multicenter research network study. J Am Acad Dermatol. 2021;84(1):70–75.
   PubMed Web of Science ®Google Scholar
• Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Network Open. 2021;4(10):e2129639.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Zhou X, Rubin DT, et al. Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study. J Rheumatol. 2022;49(3):320–329.
   PubMed Web of Science ®Google Scholar
• Kokkotis G, Kitsou K, Xynogalas I, et al. Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments. Aliment Pharmacol Ther. 2022;55(2):154–167.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–768.
   PubMed Web of Science ®Google Scholar
• Jia F, Wang G, Xu J, et al. Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia. Aging (Albany NY). 2021;13(21):23895–23912.
   PubMedGoogle Scholar
• Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567.
   PubMed Web of Science ®Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635–641.
   PubMed Web of Science ®Google Scholar
• Mangalmurti N, Hunter CA. Cytokine storms: understanding COVID-19 immunity. Immunity. 2020;53(1):19–25.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47–62.
   PubMed Web of Science ®Google Scholar
• Wan MT, Shin DB, Winthrop KL, et al. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(2):677–679.
   PubMed Web of Science ®Google Scholar
• Kridin K, Schonmann Y, Solomon A, et al. Risk of COVID-19 infection, hospitalization, and mortality in patients with psoriasis treated by interleukin-17 inhibitors. J Dermatolog Treat. 2021;24:1–28.
   Google Scholar
• Liu Y, Zhang C, Huang F, et al. Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev. 2020;7(6):1003–1011.
   PubMed Web of Science ®Google Scholar
• Ghazavi A, Ganji A, Keshavarzian N, et al. Cytokine profile and disease severity in patients with COVID-19. Cytokine. 2021;137:155323.
   PubMed Web of Science ®Google Scholar
• Facheris P, Valenti M, Pavia G, et al. Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab. Int J Dermatol. 2020;59(8):e267–e268.
   PubMed Web of Science ®Google Scholar
• Syed MN, Shin DB, Wan MT, et al. The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: a meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(5):1523–1526.
   PubMed Web of Science ®Google Scholar
• Akiyama S, Yamada A, Micic D, et al. The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84(3):676–690.
   PubMedGoogle Scholar
• Jones ME, Kohn AH, Pourali SP, et al. The use of biologics during the COVID-19 pandemic. Dermatol Clin. 2021;39(4):545–553.
   PubMed Web of Science ®Google Scholar
• Zeng H, Wang S, Chen L, et al. Biologics for psoriasis during the COVID-19 pandemic. Front Med (Lausanne). 2021;8:759568.
   PubMedGoogle Scholar
• Hansel K, Zangrilli A, Bianchi L, et al. A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. J Eur Acad Dermatol Venereol. 2021;35(3):e169–e170.
   PubMed Web of Science ®Google Scholar
• Wang CJ, Truong AK. COVID-19 infection on IL-23 inhibition. Dermatol Ther. 2020;33(6):e13893.
   PubMed Web of Science ®Google Scholar
• Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol. 2020;34(6):e254–e255.
   PubMed Web of Science ®Google Scholar
• Benhadou F, Del Marmol V. Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient. J Eur Acad Dermatol Venereol. 2020;34(8):e363–4.
   PubMed Web of Science ®Google Scholar
• Ward M, Gooderham M. Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23. JAAD Case Rep. 2021;7:60–61.
   PubMedGoogle Scholar
• Borroni RG, Malagoli P, Gargiulo L, et al. Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol. 2021;101(11):adv00605.
   PubMedGoogle Scholar
• Garcillán B, Salavert M, Regueiro JR, et al. Response to vaccines in patients with immune-mediated inflammatory diseases: a narrative review. Vaccines (Basel). 2022;10(2):297.
   PubMed Web of Science ®Google Scholar
• Skroza N, Bernardini N, Tolino E, et al. Safety and impact of anti-COVID-19 vaccines in psoriatic patients treated with biologics: a real life experience. J Clin Med. 2021;10(15):3355.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M. Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents. Expert Opin Biol Ther. 2021;21(11):1535–1537.
   PubMed Web of Science ®Google Scholar
• Musumeci ML, Caruso G, Trecarichi AC, et al. Safety of SARS-CoV-2 vaccines in psoriatic patients treated with biologics: a real life experience. Dermatol Ther. 2022;35(1):e15177.
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Tsentemeidou A, Bakirtzi K, et al. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021;35(12):e857–e859.
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Gallo L, et al. Reply to “Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre” by Sotiriou E et al. J Eur Acad Dermatol Venereol. 2022;36(1):e11–e13.
   PubMed Web of Science ®Google Scholar
• Yatsuzuka K, Murakami M, Kuroo Y, et al. Flare-up of generalized pustular psoriasis combined with systemic capillary leak syndrome after coronavirus disease 2019 mRNA vaccination. J Dermatol. 2022;49(4):454–458.
   PubMed Web of Science ®Google Scholar
• Koumaki D, Krueger-Krasagakis SE, Papadakis M, et al. Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre. J Eur Acad Dermatol Venereol. 2022;36(6). In Print. 10.1111/jdv.17965.
   Web of Science ®Google Scholar
• Chao J-P, Tsai T-F. Psoriasis flare following ChAdOx1-S/nCoV-19 vaccination in patients with psoriasis under biologic treatment. Dermatol Sin. 2021. 10.4103/ds.ds_45_21
   Web of Science ®Google Scholar
• Wei N, Kresch M, Elbogen E, et al. New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Rep. 2022;19:74–77.
   PubMedGoogle Scholar
• Durmus O, Akdogan N, Karadag O, et al. Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis. Dermatol Ther. 2022;35(5):e15363.
   PubMed Web of Science ®Google Scholar
• Pavia G, Gargiulo L, Spinelli F, et al. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. J Eur Acad Dermatol Venereol. 2022;36(7). In Print. 10.1111/jdv.18032.
   PubMed Web of Science ®Google Scholar
• Huang YW, Tsai TF. Exacerbation of psoriasis following COVID-19 vaccination: report from a single center. Front Med (Lausanne). 2021 Dec 23;8:812010.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270–278.
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653.
   PubMed Web of Science ®Google Scholar
• Johnson-Huang LM, Suárez-Fariñas M, Pierson KC, et al. A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol. 2012;132(4):1177–1187.
   PubMed Web of Science ®Google Scholar
• Spinelli FR, Favalli EG, Garufi C, et al. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther. 2022;24(1):21.
   PubMed Web of Science ®Google Scholar
• Venerito V, Stefanizzi P, Fornaro M, et al. Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. RMD Open. 2022;8(1):e001847.
   PubMed Web of Science ®Google Scholar
• Damiani G, Allocco F, Malagoli P, . COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers. Clin Exp Dermatol. 2021;46(6):1106–1108.
   PubMed Web of Science ®Google Scholar
• Cristaudo A, Graceffa D, Pimpinelli F, et al. Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs. J Eur Acad Dermatol Venereol. 2022;36(4):e266–e268.
   PubMed Web of Science ®Google Scholar
• Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021;3(9):e627–e637.
   PubMedGoogle Scholar
• Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. Lancet Rheumatol. 2022;4(1):e42–e52.
   PubMedGoogle Scholar
• Piros ÉA, Cseprekál O, Görög A, et al. Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study. Dermatol Ther. 2022;35(5):e15408.
   PubMed Web of Science ®Google Scholar
• Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021 Oct;80(10):1306–1311.
   PubMed Web of Science ®Google Scholar
• Simon D, Tascilar K, Fagni F, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. Ann Rheum Dis. 2021;80(10):1312–1316.
   PubMed Web of Science ®Google Scholar
• Al-Janabi A, Littlewood Z, Griffiths CEM, et al. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. Br J Dermatol. 2021;185(3):646–648.
   PubMed Web of Science ®Google Scholar
• Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1339–1344.
   PubMed Web of Science ®Google Scholar
• Wieske L, van Dam KPJ, Steenhuis M, et al. Immunity against SARS-CoV-2 study group. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 2022;4(5):e338–e350.
   PubMedGoogle Scholar
• Boekel L, Stalman EW, Wieske L, et al. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatol. 2022;4(6):e417–e429.
   PubMedGoogle Scholar
• Gelfand JM, Armstrong AW, Bell S, et al. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 2-advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021;84(5):1254–1268.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Armstrong AW, Bell S, et al. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 1. J Am Acad Dermatol. 2020;83(6):1704–1716.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. COVID-19 task force guidance statements. [cited 2022 Jul 9th]. Available from: https://www.psoriasis.org/covid-19-task-force-guidance-statements/
   Google Scholar
• PsoProtect. [cited 2022 Jun 7]. Available from: https://psoprotect.org/
   Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498.
   PubMed Web of Science ®Google Scholar
• Mehta D, Lim HW. Ultraviolet B phototherapy for psoriasis: review of practical guidelines. Am J Clin Dermatol. 2016;17(2):125–133.
   PubMed Web of Science ®Google Scholar
• Li Y, Ashcroft T, Chung A, et al. Risk factors for poor outcomes in hospitalised COVID-19 patients: a systematic review and meta-analysis. J Glob Health. 2021;11:10001.
   PubMed Web of Science ®Google Scholar
• Raeisi T, Mozaffari H, Sepehri N, et al. The negative impact of obesity on the occurrence and prognosis of the 2019 novel coronavirus (COVID-19) disease: a systematic review and meta-analysis. Eat Weight Disord. 2022;27(3):893–911.
   PubMed Web of Science ®Google Scholar